Avance Biosciences opened a Potency and Cell‑Based Assay Center of Excellence in Houston to centralize GMP‑compliant potency assay development and testing for biologics, RNA therapeutics, vaccines and cell and gene therapies. The facility aims to accelerate assay qualification, GMP testing, and reduce turnaround times for clients, company officials said. Meanwhile, reports show BioNexus Gene Lab secured $500 million to step into manufacturing capacity expansion—moves that together underline industry investment in analytical and manufacturing infrastructure needed to support next‑generation biologics and small‑batch personalized modalities.